PMC:7394275 / 5065-6719 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":162,"end":166},"obj":"Body_part"},{"id":"T4","span":{"begin":997,"end":1003},"obj":"Body_part"},{"id":"T5","span":{"begin":1097,"end":1103},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma25056"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma312401"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma312401"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":997,"end":1003},"obj":"Body_part"},{"id":"T2","span":{"begin":1097,"end":1103},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-PubTator

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T27","span":{"begin":253,"end":255},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T28","span":{"begin":450,"end":452},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T29","span":{"begin":1088,"end":1089},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T30","span":{"begin":1120,"end":1122},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":623,"end":626},"obj":"Chemical"},{"id":"T17","span":{"begin":768,"end":771},"obj":"Chemical"},{"id":"T19","span":{"begin":1349,"end":1360},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A16","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A18","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":1069,"end":1082},"obj":"http://purl.obolibrary.org/obo/GO_0016046"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T32","span":{"begin":0,"end":153},"obj":"Sentence"},{"id":"T33","span":{"begin":154,"end":454},"obj":"Sentence"},{"id":"T34","span":{"begin":455,"end":603},"obj":"Sentence"},{"id":"T35","span":{"begin":604,"end":821},"obj":"Sentence"},{"id":"T36","span":{"begin":822,"end":945},"obj":"Sentence"},{"id":"T37","span":{"begin":946,"end":1124},"obj":"Sentence"},{"id":"T38","span":{"begin":1125,"end":1433},"obj":"Sentence"},{"id":"T39","span":{"begin":1434,"end":1654},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":523,"end":532},"obj":"Phenotype"},{"id":"T8","span":{"begin":623,"end":626},"obj":"Phenotype"},{"id":"T9","span":{"begin":768,"end":771},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

2_test

{"project":"2_test","denotations":[{"id":"32737747-32086938-73473601","span":{"begin":149,"end":151},"obj":"32086938"},{"id":"32737747-14552675-73473602","span":{"begin":450,"end":452},"obj":"14552675"},{"id":"32737747-32160910-73473603","span":{"begin":599,"end":601},"obj":"32160910"},{"id":"32737747-30076119-73473604","span":{"begin":817,"end":819},"obj":"30076119"},{"id":"32737747-32220206-73473605","span":{"begin":1120,"end":1122},"obj":"32220206"},{"id":"32737747-30506286-73473606","span":{"begin":1303,"end":1305},"obj":"30506286"}],"text":"Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have the similar prevalence, biological and clinical characteristics [15]. Looking back on SARS in 2003, we found the incidence of fungal infection in SARS patients was 14.8–27%, which was even higher in severely ill ones, up to 21.9–33% [16, 17], meanwhile, fungal infection was the main cause of death for SARS patients, accounting for 25–73.7% in all causes of death [18]. Besides, in the past decade, increasing reports of severe influenza pneumonia resulting in ARDS complicated by fungal infection were published [19]. One research found IPA was diagnosed in 83 (19%) of 432 patients admitted with influenza, which was higher in immunocompromised patients (32%), and in the event of IPA, the mortality will increase from 28 to 51% [20]. However, as for fungal co-infection in COVID-19 patients, only few studies have reported it, which may have been neglected. Clinically, many COVID-19 patients did not undergo sputum fungal assessment at the beginning, moreover, it is difficult to detect fungus with a single sputum fungal culture [11]. With the disease aggravating, it is easy to attribute the severe respiratory symptoms to COVID-19, at the most considering of the co-infection with bacterium or even mycoplasma [21] which usually leads to the in-time use of antibiotics, while the diagnosis of fungal infection is always delayed or neglected. Based on the experience of SARS in 2003 and the cases of invasive aspergillosis combined with severe influenza, it is critically important to pay attention to the probability of COVID-19 accompanied by fungal infections."}

PMC:7394275 / 5065-6719 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7394275 / 5065-6719 JSON TXT